Financial Performance - Revenue for the fiscal year 2022 was 778.639 million in 2021[6]. - Gross profit for 2022 was 491.773 million in 2021[6]. - The company reported a net loss of 351.295 million in 2021[6]. - The group recorded a net loss of 436.5 million[22]. - The group achieved a global revenue of 840.8 million for the year ended December 31, 2022, representing a 15.6% increase compared to 2021, excluding currency effects[102]. - The company reported a loss of 436.5 million[102]. Assets and Liabilities - Total assets as of 2022 were 4.380 billion in 2021[11]. - Non-current assets increased to 1.994 billion in 2021[11]. - Current liabilities rose to 546.757 million in 2021[11]. - The debt-to-asset ratio rose from 49.4% as of December 31, 2021, to 55.1% as of December 31, 2022[77]. - The net current asset value decreased to 1,840.0 million as of December 31, 2021[78]. Market Reach and Growth - The company operates in over 20,000 hospitals worldwide, showcasing its extensive market reach[12]. - The company achieved a global business revenue growth of 15.6% year-on-year, reaching 419.8 million, reflecting higher investments in ongoing and new R&D projects[68]. - The company is actively pursuing new product development to meet the evolving needs of the healthcare market[91]. Product Development and Approvals - A total of 22 products received approval from the National Medical Products Administration in China, with 4 products included in the special approval process for innovative medical devices[19]. - The company completed the TARGET IV NA clinical study for the Firehawk® drug-eluting stent system, which will support regulatory approvals in the U.S. and Canada[17]. - The company has established over 40 clinical application and training centers nationwide for medical robotics education and training[18]. - The company has obtained 5 EU CE certifications for key products in the aortic and peripheral vascular intervention segment, enhancing market coverage[30]. Leadership and Management - The company has a strong leadership team with diverse backgrounds in finance, technology, and business development, ensuring effective management and strategic direction[89]. - The Chief Financial Officer, Mr. Sun Hongbin, has over 25 years of financial experience, having served as Director and General Manager of Takeda China from 2006 to 2010[90]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[91]. Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[168]. - The board consists of seven members, including one executive director, three non-executive directors, and three independent non-executive directors as of December 31, 2022[171]. - The company has complied with all applicable code provisions of the corporate governance code throughout the fiscal year ending December 31, 2022, except for the separation of the roles of chairman and CEO[173]. Environmental and Social Responsibility - The company has established an Environmental, Health, and Safety (EHS) management committee to oversee its environmental protection responsibilities[103]. - The company has a strong focus on sustainable development and green operations[103]. - The company made donations amounting to approximately $8.1 million during the fiscal year ending December 31, 2022[163]. Financial Risks and Challenges - The company is exposed to various financial risks, including credit risk, interest rate risk, liquidity risk, and currency risk[105]. - Market risks include pressure on product pricing due to government policies and uncertainties in medical insurance reimbursement levels in China[106]. - The company has faced challenges due to the COVID-19 pandemic and high inflation, impacting global economic recovery[102].
微创医疗(00853) - 2022 - 年度财报